| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN DIEGO, November 9, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dr... |
| 14 Aug 2026 |
8-K: Other Events
TD Securities (USA) LLCGuggenheim Securities, LLCOppenheimer & Co. Inc. |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN DIEGO — August 6, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-dri... |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 16, 2026, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 49,453,766 shares of common stock were present online or represented ... |
| 27 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Effective May 22, 2026, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director. Ms. Campbell's initial t... |
| 21 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
SAN DIEGO — May 12, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approa... |
| 05 May 2026 |
8-K: Regulation FD Disclosure; Other Events
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer |
| 17 Apr 2026 |
8-K: Regulation FD Disclosure
Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 |
| 09 Apr 2026 |
8-K: Regulation FD Disclosure; Other Events
2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of th... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
SAN DIEGO — March 26, 2026 — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment appr... |
| 09 Jan 2026 |
8-K: Regulation FD Disclosure; Other Events
2 Zentalis Pharmaceuticals, Inc. (“we,” “us,” “our,” “Zentalis” or the “Company”) cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of th... |
| 15 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Other Events
On December 15, 2025, Karan Takhar, who serves as Senior Managing Director and head of Life Sciences investing at Matrix Capital Management Company, L.P., resigned from his position as a member of the Board of Directors of Zentalis Pharm... |
| 10 Nov 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback |
| 26 Aug 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Seasoned life sciences legal executive brings extensive public company experience, including broad strategic and financial transaction expertise |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback |
| 18 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2025, Zentalis Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 58,212,103 shares of common stock were present online or represented ... |
| 02 Jun 2025 |
8-K: Regulation FD Disclosure
METHODS Figure 3. Phase 1, Single‑Arm, Open‑Label, Multicenter, Dose‑Escalation Study Design and Patient Flow Key Eligibility Criteria • Age ≥18 years • Metastatic/Stage IV CRC • BRAFV600E mutation • Measurable disease per RECIST v1.1 • ... |
| 20 May 2025 |
8-K: Regulation FD Disclosure
Zentalis Pharmaceuticals, Inc. plans to participate and present in the following investor events: |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC |
Loading...